S100/calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 7, 2014, Pages 1399-1411

  Yan, Ling ^a   Mathew, Liby ^a   Chellan, Bijoy ^a   Gardner, Brandon ^a   Earley, Judy ^a   Puri, Tipu S ^a   Hofmann Bowman, Marion A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

glycosylation end products advanced; hypertrophy left ventricular; renal insufficiency chronic; S100 proteins

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALGRANULIN; CALGRANULIN A; CALGRANULIN B; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN; PROTEIN S 100; PROTEIN S100A12; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; ARTERIAL WALL THICKNESS; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BLOOD VESSEL CALCIFICATION; BONE MARROW CELL; C57BL 6 MOUSE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; IN VITRO STUDY; INFLAMMATION; METAPLASIA; MOLECULAR PATHOLOGY; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; UREMIA; WILD TYPE;

GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERTROPHY, LEFT VENTRICULAR; RENAL INSUFFICIENCY, CHRONIC; S100 PROTEINS;

ANIMALS; AORTIC VALVE; CALCINOSIS; CALGRANULIN A; CALGRANULIN B; CELLS, CULTURED; DIASTOLE; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; GENOTYPE; HEART VALVE DISEASES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTE L1 ANTIGEN COMPLEX; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIUM; PHENOTYPE; RECEPTORS, IMMUNOLOGIC; RENAL INSUFFICIENCY, CHRONIC; S100 PROTEINS; SCLEROSIS; SIGNAL TRANSDUCTION; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84903138414     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303508     Document Type: Article

References (46)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
2. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, Urakami M, Iwasaka T, Matsubara H. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol. 2009;29:18-24.
3. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012;220:208-214.
4. Shiotsu Y, Mori Y, Hatta T, Maki N, Iida K, Matsuoka E, Kado H, Ishida R, Kishimoto N, Tamagaki K, Nishimura M, Iwamoto N, Ono T, Matsubara H, Kosaki A. Plasma S100A12 levels and peripheral arterial disease in end-stage renal disease. Nephron Extra. 2011;1:242-250.
5. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:2213-2219.
6. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, Matsuoka E, Kishimoto N, Tamagaki K, Matsubara H, Kosaki A. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:718-723.
7. Shiotsu Y, Mori Y, Nishimura M, Hatta T, Imada N, Maki N, Iida K, Iwamoto N, Matsuoka E, Tamagaki K, Kosaki A. Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan. BMC Nephrol. 2013;14:16.
8. Hara M, Ando M, Morito T, Nokiba H, Iwasa Y, Tsuchiya K, Nitta K. S100A12 gene expression is increased in peripheral leukocytes in chronic kidney disease stage 4-5 patients with cardiovascular disease. Nephron Clin Pract. 2013;123:202-208.
9. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
10. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010;106:842-853.
11. Yan L, Bjork P, Butuc R, Gawdzik J, Earley J, Kim G, Hofmann Bowman MA. Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Atherosclerosis. 2013;228:69-79.
12. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem. 1991;266:7706-7713.
13. Vogl T, Pröpper C, Hartmann M, Strey A, Strupat K, van den Bos C, Sorg C, Roth J. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem. 1999;274:25291-25296.
14. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H, Lord RS, Geczy CL. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem. 2005;280:41521-41529.
15. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271.
16. Volz HC, Laohachewin D, Seidel C, Lasitschka F, Keilbach K, Wienbrandt AR, Andrassy J, Bierhaus A, Kaya Z, Katus HA, Andrassy M. S100a8/a9 aggravates post-ischemic heart failure through activation of rage-dependent nf-kappab signaling. Basic Res Cardiol. 2012;107:250.
17. Das D, Gawdzik J, Dellefave-Castillo L, McNally EM, Husain A, Raman J, Hofmann Bowman MA. S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. J Am Coll Cardiol. 2012;60:775-785.
18. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111:959-972.
19. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G, Earley J, McNally EM. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol. 2011;31:337-344.
20. Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA. Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol. 2011;33:250-259.
21. Fuellen G, Nacken W, Sorg C, Kerkhoff C. Computational searches for missing orthologs: the case of S100A12 in mice. OMICS. 2004;8:334-340.
22. Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, Raman J, McNally EM. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res. 2010;106:145-154.
23. Chellan B, Yan L, Sontag TJ, Reardon CA, Hofmann Bowman MA. Il-22 is induced by s100/calgranulin and impairs cholesterol efflux in macrophages by down regulating abcg1. J Lipid Res. 2014;55:443-454.
24. Carlström M, Sällström J, Skøtt O, Larsson E, Wåhlin N, Persson AE. Hydronephrosis causes salt-sensitive hypertension and impaired renal concentrating ability in mice. Acta Physiol (Oxf). 2007;189:293-301.
25. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-4408.
26. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.
27. Park SH, Stenvinkel P, Lindholm B. Cardiovascular biomarkers in chronic kidney disease. J Ren Nutr. 2012;22:120-127.
28. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N. Mineralized tissue cells are a principal source of FGF23. Bone. 2007;40:1565-1573.
29. Shuvy M, Abedat S, Beeri R, Danenberg HD, Planer D, Ben-Dov IZ, Meir K, Sosna J, Lotan C. Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. Cardiovasc Res. 2008;79:492-499.
30. Shuvy M, Abedat S, Beeri R, Valitsky M, Daher S, Kott-Gutkowski M, Gal-Moscovici A, Sosna J, Rajamannan NM, Lotan C. Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure. Am J Physiol Heart Circ Physiol. 2011;300:H1829-H1840.
31. Harja E, Bu DX, Hudson BI, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest. 2008;118:183-194.
32. Isakova T, Xie H, Yang W, et al; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432-2439.
33. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545-2552.
34. Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, Quarles LD. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 2011;25:2551-2562.
35. Pöss J, Mahfoud F, Seiler S, Heine GH, Fliser D, Böhm M, Link A. FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2013;2: 211-218.
36. Scialla JJ, Lau WL, Reilly MP, et al; Chronic Renal Insufficiency Cohort Study Investigators. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 2013;83:1159-1168.
37. Nielsen JM, Kristiansen SB, Nørregaard R, Andersen CL, Denner L, Nielsen TT, Flyvbjerg A, Bøtker HE. Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/ db type 2 diabetic mice. Eur J Heart Fail. 2009;11:638-647.
38. Bucciarelli LG, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, Strauch C, Monnier VM, Yan SF, Schmidt AM, Ramasamy R. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes. 2008;57:1941-1951.
39. Tsoporis JN, Izhar S, Leong-Poi H, Desjardins JF, Huttunen HJ, Parker TG. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ Res. 2010;106:93-101.
40. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O'Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124:1783-1791.
41. Towler DA. Vascular calcification: it's all the RAGE! Arterioscler Thromb Vasc Biol. 2011;31:237-239.
42. Cecil DL, Terkeltaub RA. Arterial calcification is driven by RAGE in Enpp1-/- mice. J Vasc Res. 2011;48:227-235.
43. Rajamannan NM. Calcific aortic valve disease: cellular origins of valve calcification. Arterioscler Thromb Vasc Biol. 2011;31:2777-2778.
44. Li C, Xu S, Gotlieb AI. The progression of calcific aortic valve disease through injury, cell dysfunction, and disruptive biologic and physical force feedback loops. Cardiovasc Pathol. 2013;22:1-8.
45. Lyle AN, Remus EW, Fan AE, Lassègue B, Walter GA, Kiyosue A, Griendling KK, Taylor WR. Hydrogen peroxide regulates osteopontin expression through activation of transcriptional and translational pathways. J Biol Chem. 2014;289:275-285.
46. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005;96:717-722.